Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Dis Colon Rectum. 2021 May;64(5):545–554. doi: 10.1097/DCR.0000000000001914

Table 2.

Adjusted hazard ratios for mortality in stage II colon cancer based on patient and tumor features.

Variable HR (95% CI) p-value
MSI-H (vs MSS/MSI-L) 0.75 (0.65-0.87) <0.001
Age (SD) 1.06 (1.05-1.06) <0.001
Female (%) 0.78 (0.72-0.85) <0.001
Race
    White Ref Ref
    Black 1.29 (1.14-1.46) <0.001
    Other 0.69 (0.56-0.87) <0.001
Institution type
    Community Cancer Program Ref Ref
    Comprehensive Community Program 0.88 (0.76-1.10) 0.066
    Academic/Research 0.80 (0.69-0.93) 0.003
    Integrated Network Cancer Program 0.89 (0.76-1.05) 0.170
Primary Payor
    Not insured Ref Ref
    Private insurance 0.72 (0.55-0.95) 0.022
    Medicaid 1.21 (0.88-1.67) 0.247
    Medicare 0.89 (0.67-1.17) 0.404
    Other Government 0.99 (0.60-1.64) 0.961
    Unknown 0.96 (0.59-1.57) 0.873
Charlson-Deyo score
    0 Ref Ref
    1 1.22 (1.12-1.34) <0.001
    2 1.83 (1.62-2.08) <0.001
    3+ 2.61 (2.23-3.05) <0.001
Primary Tumor Site
    Left colon/rectosigmoid Ref Ref
    Right colon 0.89 (0.82-0.97) 0.005
Adjuvant chemotherapy 0.90 (0.80-1.02) 0.096
T4 Stage 1.77 (1.59-1.96) <0.001
Lymphovascular Invasion
    Absent Ref Ref
    Present 1.19 (1.06-1.33) 0.003
    Unknown 1.09 (0.92-1.30) 0.331
Perineural Invasion
    Absent Ref Ref
    Present 1.40 (1.22-1.60) <0.001
    Unknown 1.01 (0.81-1.27) 0.921
Tumor Grade
    Low Grade Ref Ref
    High Grade 1.12 (0.99-1.24) 0.052
    Unknown 1.03 (0.78-1.36) 0.826
Positive Margins 1.36 (1.18-1.57) <0.001
< 12 Lymph Nodes 1.27 (1.11-1.45) <0.001